Company overview
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing CGEM with another company.
| Daily close (USD) | $15.46 |
| Market capitalization (USD) | $994,923,569.24 |
| Price / earnings (TTM) | Not reported |
| Price / book | 3.09 |
No matching rows. Clear the filter to see all records.
Read CGEM's valuation metrics
Company size
Cullinan Therapeutics, Inc. Common Stock's recorded market capitalization is $994,923,569.24. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
CGEM's recorded price-to-book ratio is 3.09. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Cullinan Therapeutics, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about CGEM. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow CGEM's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.